At #ASH2025, ECOG-ACRIN & @precogonc.bsky.social researchers will present data that could improve treatments for #AML, #ALL, #MCL, #CLL and more. View our full guide to the meeting: bit.ly/4rtkbHp #BloodCancer #leukemia #lymphoma

Geisinger Cancer Institute is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Great work to Vanderbilt University Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

@stanford-cancer.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

In honor of #LungCancer Awareness Month, learn about PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Click here for more 👉 bit.ly/49xgUR3 #LCAM #LCSM

On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25

Kudos to @virtuahealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S

Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM

Thomas Jefferson University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Marshfield Clinic is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue

Kudos to the following institutions for enrolling their first patients in #RealWorldData #PatientRegistry PrE1702: Sibley Memorial Hospital, Good Samaritan University Hospital, and Northwestern University! More info here: bit.ly/pre1702-study #LCSM #RWD #RWE

Kudos to The Valley Hospital (Luckow Pavilion) for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue

Kudos to Aurora Saint Luke’s Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue

Kudos to John H. Stroger, Jr. Hospital of Cook County for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue

University of Wisconsin Carbone Cancer Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue

Sibley Memorial Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue

Kudos to The University of Alabama at Birmingham for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue

ICYMI: Check out our round-up of recently published @eaonc.bsky.social and @precogonc.bsky.social research results. More here ➡️ bit.ly/july25research #ClinicalTrials #BreastCancer #CancerControl #CancerSurvivorship #HeadandNeck #LungCancer #Melanoma

Great work to Atlantic Health System for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM

Kudos to The Cancer Institute at Saint Francis Hospital for enrolling their 1st patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue

Good Samaritan University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Kudos to SUNY Upstate Medical University for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue

Kudos to Allegheny General Hospital for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

The Cancer Institute at St. Francis Hospital & UNC Pardee Cancer Center are now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue

Gundersen Lutheranis now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Montefiore Medical Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Carle Cancer Institute is enrolling pts in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

O'Neal Comprehensive Cancer Center at UAB is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Great work to @penncancer.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Great work to Mercyhealth Hospital and Cancer Center Janesville for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Aurora NCORP and Northwestern University are now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Great work to Regions Hospital for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Allegheny General Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Atlantic Health Consortium Community Oncology Research Program is enrolling pts in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue

Kudos to Greater Baltimore Medical Center for enrolling their first patient! ⬇️

Greater Baltimore Medical Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Aultman Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Integris Cancer Institute of Oklahoma is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

@rutgerscancer.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Bayhealth Cancer Institute's Kent & Sussex campuses & SUNY Upstate Medical University are now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo works to control EGFR pos. #LungCancer in pts not in a #ClinicalTrial. bit.ly/4hyZUue

Mercy Research (@followmercy.bsky.social) is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

@penncancer.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

@mainlinehealth.bsky.social's Lankenau Medical Center in PA is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

@virtuahealth.bsky.social in New Jersey is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Great work to UTSW Simmons Cancer Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE

Valley Health System in Northern New Jersey is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

Baptist Memorial Health Care in the Mid-South US is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more: bit.ly/4hyZUue

The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE